Tidemark’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Tidemark’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-91	Closed	-$5.77K	–	738
2025 Q1	$5.77K	Hold	91	–	–	﹤0.01%	500
2024 Q4	$6.05K	Hold	91	–	–	﹤0.01%	490
2024 Q3	$6.35K	Hold	91	–	–	﹤0.01%	474
2024 Q2	$5.9K	Sell	91 -77	-46%	-$4.88K	﹤0.01%	453
2024 Q1	$10.9K	Buy	+168	New	+$10.9K	0.01%	431

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Tidemark's PBE Position: Q2 2025 in Review

Tidemark sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2025, closing a stake of 91 shares — an estimated $5.77K sold.

Tidemark first reported a position in PBE in Q1 2024 and held it in 5 quarters. The position peaked at $10.9K in Q1 2024. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2025.

Tidemark reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2025 after selling out during the quarter.
Tidemark sold 91 Invesco Biotechnology & Genome ETF shares in Q2 2025, an estimated $5.77K.
Tidemark first reported a position in Invesco Biotechnology & Genome ETF in Q1 2024 and held it in 5 quarters.
Tidemark's Invesco Biotechnology & Genome ETF position peaked at $10.9K in Q1 2024.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2025.

Based on Tidemark's 13F filing for Q2 2025, filed 11 Aug 2025.